Search results for

Tegal Corp v Tokyo Electron Co, 58 USPQ2d 1791 (Fed Cir, May 14 2001) involves the interesting issue of what constitutes conduct contemptuous of an injunction against wilful patent infringement under US law.

Australia: MicroMedical Industries has been granted a second US patent for technology relating to a blood pump used in its artificial hearts. The patent brings the company one step closer to conducting human clinical trials of the artificial heart.

According to the Romanian Trade Mark Law no 84, art 23 and the Regulation for implementing the Law, rule 19, within three months of the date of publication of a trade mark, the owner of an earlier mark or of a well-known mark, the holder of an earlier right in a likeness or surname, a protected geographical indication or a protected industrial design or any other concerned person, may file an opposition to a published mark with the State Office for Inventions and Trade Marks.

Koos Rasser of Howrey Simon Arnold & White in Washington examines the implications of the Festo ruling on US patent practice

Rübba Palmos, of Nevinpat St Petersburg, reveals how one Russian company is holding trade mark owners to ransom thanks to a loophole in the country’s law

In the 10 years since the rebirth of democracy, Romania has made major progress. But counterfeiting of IP rights has escalated. Lucien Enescu and Ian Mocanu of Rominvent in Bucharest explain how the problem has arisen and what measures are being taken to defeat it

Romania has a new law governing the protection of plant varieties. Lucian Enescu and Cristina Popa of Rominvent in Bucharest explain how to obtain protection

Oscar M Becerril, of Becerril, Coca & Becerril, SC in Mexico City, reviews the various options available for protecting container designs in Mexico

There are an estimated 190 core biotech and 460 biotech-related companies operating in Australia Approximately 35 core biotech companies and 25 biotech-related companies are publicly listed The industry as a whole has raised about A$900 million since the previous industry report in 1999, five times more than estimated in 1998-1999 Revenues generated by core biotech companies over the past 12 months are estimated at almost A$1 billion. Human health, equipment and services, and agriculture are the sectors with the most number of products under development. In 2001 there is an estimated A$300 million of ongoing publicly funded research in biotechnology Victoria has the greatest number of core biotechnology companies (38%) New South Wales has the highest number of biotech-related companies (40%) R&D investment by Australian biotech companies in 1999-2000 was approximately A$150 million. Approximately half the biotech companies operate in the human health sector, including diagnostics and therapeutics Genomics and bio-informatics companies has more than doubled since 1999 Australia's patent system gives it a competitive advantage in attracting foreign companies to invest in the country's biotechnology industry, according to a recently released report on the growth of the sector.